EMEA-002585-PIP01-19

Key facts

Active substance
Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528)
Therapeutic area
Oncology
Decision number
P/0353/2019
PIP number
EMEA-002585-PIP01-19
Pharmaceutical form(s)
Dispersion for infusion
Condition(s) / indication(s)
Treatment of Multiple Myeloma
Route(s) of administration
Intravenous use
Contact for public enquiries
Janssen-Cilag International N.V

Tel.: +353 857446696
E-mail: nbuhl@ITS.JNJ.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating